Skye Bioscience to Present at the H.C. Wainwright Ophthalmology Conference
Skye Bioscience (OTCQB: SKYE) announced that Karam Takhar, VP of Corporate Development, will virtually present at the H.C. Wainwright Ophthalmology Conference on August 17 at 7:00 AM ET. The management team will also be available for one-on-one meetings during the event. Skye Bioscience develops cannabinoid-derived therapeutics aimed at addressing unmet medical needs, with its lead program targeting glaucoma, a major cause of blindness. Interested investors should contact their H.C. Wainwright representative for meeting arrangements.
- None.
- None.
SAN DIEGO, CA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat diseases with significant unmet need, announced today that Karam Takhar, VP of Corporate Development and Investor Relations, Skye Bioscience is scheduled to present virtually in the H.C. Wainwright Ophthalmology Conference on Tuesday, August 17 at 7:00 AM ET.
Members of the management team will also be available for virtual one-on-one meetings during the conference. Investors participating in the conference who are interested in meeting with the team should contact their H.C. Wainwright representative.
About Skye Bioscience
Skye Bioscience Inc. is a biopharmaceutical company unlocking the pharmaceutical potential of cannabinoids through the development of its proprietary, cannabinoid-derived molecules to treat diseases with significant unmet needs. The company’s lead program, THCVHS, is focused on treating glaucoma, the world’s leading cause of irreversible blindness. For more information, please visit: www.skyebioscience.com.
CONTACT
Karam Takhar
VP, Corporate Development & Investor Relations
Email: ir@skyebioscience.com
Phone: (858) 410-0266
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements, including statements regarding our product development, business strategy, timing of clinical trials and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
FAQ
When is Skye Bioscience's presentation at the H.C. Wainwright Ophthalmology Conference?
Who will represent Skye Bioscience at the upcoming conference?
What is the focus of Skye Bioscience's lead program?
What is the stock symbol for Skye Bioscience?
How can investors meet with Skye Bioscience at the conference?
